Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (221-230 of 280) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesOwen A O'Connor, Steven Horwitz, Paul Hamlin, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology GroupLouis S Constine, Joachim Yahalom, Andrea K Ng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Blood|January 9, 2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphomaAntonio Omuro, Denise D Correa, Lisa M DeAngelis, et al.
Blood|May 1, 1997
Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trialC H Moskowitz, P Stiff, M S Gordon, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaRobert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 17, 2015
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow TransplantationMiguel-Angel Perales, Izaskun Ceberio, Philippe Armand, et al.
Leukemia & Lymphoma|September 10, 2023
Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphomaParastoo B Dahi, Sheila Kenny, Jessica Flynn, et al.
Blood|December 13, 2017
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaAlex F Herrera, Alison J Moskowitz, Nancy L Bartlett, et al.
Pageof 28

Showing results (221-230 of 280) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesOwen A O'Connor, Steven Horwitz, Paul Hamlin, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology GroupLouis S Constine, Joachim Yahalom, Andrea K Ng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Blood|January 9, 2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphomaAntonio Omuro, Denise D Correa, Lisa M DeAngelis, et al.
Blood|May 1, 1997
Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trialC H Moskowitz, P Stiff, M S Gordon, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaRobert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 17, 2015
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow TransplantationMiguel-Angel Perales, Izaskun Ceberio, Philippe Armand, et al.
Leukemia & Lymphoma|September 10, 2023
Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphomaParastoo B Dahi, Sheila Kenny, Jessica Flynn, et al.
Blood|December 13, 2017
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaAlex F Herrera, Alison J Moskowitz, Nancy L Bartlett, et al.
Pageof 28